🇺🇸 FDA
Pipeline program

Vedolizumab

2018-002794-21

Approved mab active

Quick answer

Vedolizumab for Ulcerative Colitis is a Approved program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 9 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Ulcerative Colitis
Phase
Approved
Modality
mab
Status
active

Clinical trials